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Abstract
Objective The aim of this study was to evaluate associations between pretreatment physical status parameters and tolerance 
of concurrent chemoradiation (cCHRT) and survival among patients with stage III non-small cell lung cancer (NSCLC).
Methods A retrospective cohort study was conducted among patients with stage III NSCLC who had received cCHRT 
between 2006 and 2015. Multivariate independent associations were analysed between the pretreatment parameters age, 
Charlson comorbidity index, World Health Organization performance status (WHO performance status), body mass index 
(BMI), fat-free mass index (FFMI), maximal handgrip strength, forced expiratory volume in one second and carbon monoxide 
lung diffusion capacity on the one hand with tolerance of cCHRT (defined as a received radiation dose at least equal to the 
prescribed radiation dose) and survival on the other hand.
Results 527 of 577 patients (91.3%) tolerated cCHRT. A WHO performance status ≥ 2 (odds ratio (OR) 0.43) and 
BMI < 18.5 kg/m2 (OR 0.36) were associated with poorer tolerance of cCHRT. In the total group, a WHO performance status 
≥ 2 (hazard ratio (HR) 1.73), low FFMI (HR 1.23) and intolerance of cCHRT (HR 1.55) were associated with poorer survival.
Conclusion In patients with stage III NSCLC receiving cCHRT, poor WHO performance status and BMI < 18.5 kg/m2 were 
independently associated with tolerance of cCHRT. Physical status parameters and intolerance of cCHRT were independently 
associated with poorer survival. Besides using this information for treatment decisions, optimizing physical status in patients 
at risk for intolerance of cCHRT might be a next step for improving treatment outcomes.
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Introduction
Lung cancer is the fourth most common type of cancer in 
the Netherlands [1], with 14,500 newly diagnosed patients 
in 2017 [2]. Non-small cell lung cancer (NSCLC) accounts 
for 75% of all lung cancers [2]. About one-fourth pre-
sent with stage III which has a poor five-year survival rate 
[3]. The preferred treatment for relatively fit patients with 
stage III NSCLC is concurrent chemoradiation (cCHRT) 
[4]; however, this treatment option is very intensive and 
often accompanied by serious complications, including 
hospitalization and mortality [5].
The majority of patients are older (≥ 70 years). Patients 
at high risk for intolerance of CHRT are characterized as 
aged ≥ 70 years and those suffering from anorexia, dys-
phagia, fatigue and physical inactivity [9–11]. Although a 
geriatric assessment might identify older patients who are 
at risk for treatment complications [12], it is still unclear 
to what extent these tests individually, or in combination, 
are associated with treatment tolerance in patients with 
NSCLC [13–16]. Evidence regarding treatment options 
and outcomes are scarce for older patients with NSCLC 
and evidence-based insights are highly needed for this vul-
nerable population. Older patients are under-represented 
in clinical trials, and those older patients who are included 
are generally selected fit patients without comorbid-
ity. This means that the external validity of clinical trial 
results for the real-world population of older patients with 
cancer is low [6], especially since polypharmacy, frailty, 
poor performance status, long-term physical inactivity and 
smoking-related comorbidities characterize patients with 
stage III NSCLC [5, 7, 8].
It is, therefore, important to gain real-world insight into 
modifiable parameters that might be prognostic for tolerance 
of cCHRT and survival and identify patients at high risk for 
poor tolerance of cCHRT. Preferably, such parameters should 
be easily measured and cost-effective with a minimal bur-
den for the patient. Such information can be used by medical 
specialists for identifying patients who are expected to toler-
ate cCHRT, which is important for shared decision-making. 
The aim of this study was to gain insight into the associations 
between pretreatment physical status parameters and tolerance 
of cCHRT and survival among patients with stage III NSCLC 
in everyday clinical practice.




This project concerned a retrospective cohort study for 
which anonymous data from the medical records from a 
clinic for radiotherapy were used. All patients who under-
went cCHRT for stage III NSCLC between 2006 and 2015 
and who had no objection for the use of their usual care data 
for research purposes were included. Baseline measurements 
and physical status parameters were usually scheduled on 
the day of the first irradiation. The internal review board of 
a clinic for radiotherapy decided that this study met their 
ethical policies and the regulations of the Dutch government.
Patients and Data Collection
Patients aged ≥ 18  years with stage III NSCLC, who 
received primary cCHRT between 2006 and 2015 in two 
teaching hospitals, two non-teaching hospitals or a univer-
sity medical centre, were included. Clinical tumour stag-
ing was performed according to the 7th TNM staging of 
the International Association for the Study of Lung Cancer 
[17]. NSCLC was classified as squamous cell carcinoma, 
adenocarcinoma, large cell carcinoma and not otherwise 
specified. The following pretreatment patient characteris-
tics and physical status parameters were collected from the 
electronic patient records: sex, age, body mass index (BMI), 
fat-free mass index (FFMI), forced expiratory volume in one 
second  (FEV1), carbon monoxide lung diffusion capacity 
(DLCO), World Health Organization (WHO) performance 
status, Charlson comorbidity index and maximal handgrip 
strength. In addition, prescribed and received radiation dose, 
date of diagnosis, date of first and last irradiation and date of 
death or last registration were collected. After data collec-
tion, all data were checked for completeness and accuracy.
Treatment Protocol
cCHRT was defined as treatment with chemotherapy and 
radiotherapy with any overlap between the two modalities. 
After one or two chemotherapy cycles, radiotherapy was 
given to the primary tumour and lymph nodes [18]. In the 
first three weeks, 30 fractions of 1.5 Gy (Gy) were given 
twice daily, followed by fractions of 2 Gy once daily, with 
a minimum dose of 54 Gy and a maximum of 69 Gy [19]. 
A mean radiation dose of 65 Gy delivered to the tumour 
and affected lymph nodes was given within 5.5 weeks. 
This corresponds to a biological equivalent of 72 Gy given 
in 36 daily fractions in 7.2 weeks [20].
Pretreatment Physical Status Parameters
Anthropometry and Body Composition
Bioelectrical impedance analysis (Omron Healthcare Group, 
Hoofddorp, The Netherlands) with a single-frequency 
(50 kHz) was used for estimating body composition [21, 
22]. Patients were standing with legs apart and arms straight 
forward, holding the device with both hands. Results are 
automatically corrected for body height, body mass, Fat-free 
mass (FFM), sex and age. Body mass index was catego-
rized as underweight (< 18.5 kg/m2) or normal weight/over-
weight (≥ 18.5 kg/m2) [23]. The fat-free mass index FFMI 
(kg/m2) is a body height-adjusted assessment of FFM. Low 
FFMI was defined as a FFMI < 17 kg/m2 in male patients 
and < 15 kg/m2 in female patients, based on  10th percentile 
values for healthy subjects [24].
Lung Function
FEV1 and DLCO measurements were performed by a pul-
monary function technician and expressed as a percentage 
of predicted based on sex and age [25]. Using spirometry, 
patients were asked to breathe in as deeply as possible and 
then exhale as hard, quickly and long as possible [26, 27]. 
The DLCO is a medical test that determines how much oxy-
gen travels from the alveoli of the lungs to the blood stream 
[27]. Scores ≤ 80% of predictive for  FEV1 and DLCO were 
classified as low [28].
Physical Functioning
The WHO performance status was assessed by the radiation 
oncologist and used to indicate the level of physical func-
tioning. Patients with a score ≥ 2 were classified as having 
a poor performance status [29]. The Charlson comorbidity 
index was extracted from the medical records and classified 
as none to mild comorbidity (score 0–3) and severe comor-
bidity (score ≥ 4) [30]. Handgrip strength as an indication 
of overall muscle strength was measured with a handheld 
dynamometer (JAMAR Hydraulic Hand Dynamometer, JA 
Preston Corporation, Jackson, MI, USA) [31]. Patients were 
seated in a chair with their elbow flexed at 90° and the fore-
arm in the neutral position without any arm support from 
the chair [32]. A value below the  10th percentile of the UK 
Biobank reference values, was considered as low handgrip 
strength [33].
Outcome Variables
Tolerance of cCHRT was classified as ‘yes’ when the 
received radiation dose was at least equal to the prescribed 
radiation dose. Five-year survival was defined as the time 
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from diagnosis to death of any cause or to date of last follow-
up with a maximum of five years. Last date for checking 
date of death using the local hospital data registration or 
the Dutch Municipal Personal Records Database was June 
1st 2019.
Statistical Analyses
Data were analysed using IBM SPSS Statistics version 24 
(IBM Corp., Armonk, N.Y., USA). Descriptive statistics 
were used to summarize patient characteristics and cross-
tabulations were used to analyse associations between 
pretreatment physical status parameters and tolerance of 
cCHRT using  chi2 tests (P < 0.05 two sided). Univariate and 
multivariate binary logistic regression analyses were per-
formed for analysing the associations between pretreatment 
physical status parameters and tolerance of cCHRT. In order 
to ensure sufficient power, the ‘one in ten rule’ was applied. 
The rule states that one predictive variable can be studied 
for every ten events [34]. In this study, nine associated vari-
ables were studied. In case these were all included in mul-
tivariable analyses, a minimum number of 90 events should 
have occurred. Age, sex and pretreatment physical status 
parameters with a P value < 0.10 in the univariate analyses 
were selected for the multivariate analyses. The odds ratio 
(OR) and corresponding 95% confidence interval (CI) was 
displayed for each parameter. An OR < 1.0 indicated poorer 
tolerance of cCHRT. Overall survival during a five-year 
follow-up period was analysed according to Kaplan–Meier, 
and significant differences between groups were assessed by 
the log-rank test. Univariate and multivariate hazard ratios 
(HRs) and 95% CI for associations between physical status 
parameters and survival were calculated by Cox proportional 
hazards analyses. Age, sex and pretreatment physical status 
parameters with a P value < 0.10 in the univariate analy-
ses were selected for the multivariate regression analyses. 
Poorer survival was indicated by a HR > 1.0. In multivari-
ate analyses (backward conditional method; Pin = 0.10, 
Pout = 0.10), variables that were significant in univariate 
analyses were included. It was assumed that the associa-
tions between physical status parameters and survival could 
differ between sex and age groups. Therefore, multivariate 
analyses for overall survival were also stratified according 
to sex and age. P values < 0.10 were considered statistically 
significant.
Results
Data of 577 patients with stage III NSCLC, 357 male 
patients (61.9%) and 220 female patients (38.1%) with a 
mean age of 63.6 (standard deviation (SD) 9.2) years receiv-
ing cCHRT were available for analysis. In Table 1, baseline 
characteristics of patients are summarized according to the 
tolerance of cCHRT. WHO performance status 0–1, nor-
mal/overweight and normal handgrip strength were signifi-
cantly more present among patients who tolerated cCHRT 
(P < 0.05). Due to the high proportion of missing cases, 
 FEV1 and DLCO were excluded from multivariable analy-
ses (Table1).
Tolerance of cCHRT
A total of 50 patients (8.7%) did not tolerate cCHRT. In 
univariate regression analyses, patients being underweight 
had a significantly poorer tolerance of cCHRT compared to 
patients with normal weight/overweight (OR 0.32). Patients 
with WHO performance status ≥ 2 had a significantly poorer 
tolerance of cCHRT compared to patients with WHO perfor-
mance status 0–1 (OR 0.37). Finally, low handgrip strength 
was associated with poor tolerance of cCHRT (OR 0.52). In 
multivariable analyses, being underweight (OR 0.36) and 
WHO performance status ≥ 2 (OR 0.43) remained signifi-
cantly associated with poorer tolerance of cCHRT. Results 
of the univariate and multivariate regression analyses for 
tolerance of cCHRT are shown in Table 2.
Overall Survival
Median overall survival for the whole group was 23 months, 
and at the time of analysis after five years, 404 patients 
(70%) had died. Median overall survival was 23 months 
for those who tolerated cCHRT and 11 months for those 
who did not tolerate cCHRT (P = 0.007, Fig. 1a). The one-, 
three- and five-year survival rates for the whole group were 
69%, 38% and 30%, respectively. In univariate analyses, 
age (HR 1.23), male sex (HR 1.24), low FFMI (HR 1.27), 
DLCO < 80% (HR 1.42), WHO performance status ≥ 2 (HR 
1.91), low handgrip strength (HR 1.32) and cCHRT intoler-
ance (HR 1.56) were significantly associated with poorer 
survival. The following factors were analysed for their 
association with survival in multivariable analyses: age, 
sex, FFMI, WHO performance status, handgrip strength 
and tolerance of cCHRT were analysed for their association 
with survival in multivariable analyses. Age ≥ 70 years (HR 
1.22), WHO performance status ≥ 2 (HR 1.73), low FFMI 
(HR 1.23) and cCHRT intolerance (HR 1.55) remained sig-
nificantly associated with poor survival. The results of uni-
variate and multivariate Cox regression analyses for survival 
are shown in Table 3.
Overall Survival Stratified for Sex and Age
Median overall survival was significantly lower in 
male patients compared to female patients (21 versus 
26 months; P = 0.037; Fig. 1b). In male patients, WHO 
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Table 1  Pretreatment patient 
characteristics and physical 
status parameters according to 
tolerance of cCHRT
Data are presented as mean ± SD or n (%)
BMI body mass index, DLCO diffusing capacity for carbon monoxide, FEV1 forced expiratory volume in 
1 s, FFMI fat-free mass index, SD standard deviation, WHO World Health Organization
a No: received radiation dose was less than the prescribed radiation dose
b Yes: received radiation dose was at least equal to the prescribed radiation dose
c Males FFMI < 17 kg/m2 and females < 15 kg/m2
d < 10th percentile of established normative values (35)
e Chi2 test was calculated without missing values
Variable, number (%) Tolerance of cCHRT
Noa (n = 50) Yesb (n = 527) P value
Age (years) 63.9 ± 8.9 (45 to 80) 63.5 ± 9.2 (32 to 85)
 < 70 years 35 (70.0) 368 (69.8) 0.98
 ≥ 70 years 15 (30.0) 159 (30.2)
Sex
 Male 35 (70.0) 322 (61.1) 0.22
 Female 15 (30.0) 205 (38.9)
Histology
 Adenocarcinoma 15 (30.0) 139 (26.4) 0.47
 Squamous cell carcinoma 20 (40.0) 173 (32.8)
 Large cell carcinoma 4 (8.0) 82 (15.6)
 Non-small cell lung cancer 9 (18.0) 120 (22.8)
 No histological diagnosis 2 (4.0) 13 (2.5)
WHO performance status
 0–1 43 (86.0) 478 (90.7) 0.02e
 ≥ 2 7 (14.0) 29 (5.5)
 Unknown 0 (0.0) 20 (3.8)
Charlson comorbidity index
 0–3 25 (50.0) 299 (56.7) 0.36
 ≥ 4 25 (50.0) 228 (43.3)
BMI
 Underweight (< 18.5 kg/m2) 7 (14.0) 26 (4.9) 0.01
 Normal/overweight (≥ 18.5 kg/m2) 43 (86.0) 501 (95.1)
FFMI
 Normal FFMI 35 (70.0) 395 (75.0) 0.52e
 Low  FFMIc 13 (26.0) 118 (22.4)
 Unknown 2 (4.0) 14 (2.7)
Handgrip strength
 Normal 36 (72.0) 430 (81.6) 0.05e
  Lowd 13 (26.0) 80 (15.2)
 Unknown 1 (2.0) 17 (3.2)
FEV1
 < 80% of predicted 25 (50.0) 191 (36.2) 0.18e
 ≥ 80% of predicted 20 (40.0) 233 (44.2)
 Unknown 5 (10.0) 109 (19.5)
DLCO
 < 80% of predicted 32 (64.0) 278 (52.8) 0.44e
 ≥ 80% of predicted 9 (18.0) 106 (20.1)
 Unknown 9 (18.0) 143 (27.1)
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performance status ≥ 2 (HR 1.54), low FFMI (HR 1.60) 
and cCHRT intolerance (HR 1.85) were significantly asso-
ciated with worse survival, whereas in female patients only 
WHO performance status ≥ 2 (HR 2.56) was significantly 
associated with worse survival (Table 4). Median overall 
survival was 24 months for patients aged < 70 years and 
19 months for those aged ≥ 70 years (P = 0.050; Fig. 1c). 
In patients aged < 70 years, WHO performance status ≥ 2 
(HR 1.81), low handgrip strength (HR 1.47) and cCHRT 
intolerance (HR 1.89) were significantly associated with 
worse survival, whereas in patients aged ≥ 70 years, only 
age per year as a continuous variable (HR 1.07) and low 
FFMI (HR 1.60) were significantly associated with worse 
survival (Table 4).
Discussion
Results from this study demonstrated that several physical 
status parameters were associated with outcome follow-
ing cCHRT. In total, 8.7% of the patients did not tolerate 
cCHRT, especially those with poor WHO performance 
status or BMI < 18.5 kg/m2. Physical status parameters and 
tolerance of cCHRT were also associated with survival; 
Table 2  Univariate and multivariate odds ratios for associations of pretreatment patient characteristics and physical status parameters with toler-
ance of cCHRT in patients with stage III NSCLC
BMI body mass index; cCHRT concurrent chemoradiation; CI confidence interval; DLCO diffusing capacity for carbon monoxide; FEV1 forced 
expiratory volume in 1 second; FFMI fat-free mass index; NI=not included; NS=not significant; NSCLC non-small cell lung cancer; OR odds 
ratio; WHO World Health Organization
a Not included when P-value ≥0.10
b Males FFMI <17 kg/m2 and females FFMI<15 kg/m2
c <10th percentile of established normative values [33]
Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Age
 < 70 years Reference 0.98 NS
 ≥ 70 years 1.01 (0.54 to 1.90)
Sex
 Male 0.67 (0.36 to 1.26) 0.22 NS
 Female Reference
WHO performance status
 0–1 Reference 0.03 Reference 0.07
 ≥ 2 0.37 (0.15 to 0.90) 0.43 (0.17 to 1.07)
Charlson comorbidity index
 0–3 Reference 0.36 NIc
  ≥ 4 0.76 (0.43 to 1.36)
BMI
 Underweight (< 18.5 kg/m2) 0.32 (0.13 to 0.78) 0.01 0.36 (0.15 to 0.90) 0.03
 Normal /overweight (≥ 18.5 kg/New normative values for 
handgrip strength: results from the UK  Biobankm2)
Reference Reference
FFMI
 Normal FFMI Reference 0.52 NIc
 Low  FFMIb 0.80 (0.41 to 1.57)
Handgrip strength
 Normal Reference 0.06 NS
  Lowc 0.52 (0.26 to 1.02)
FEV1
 < 80% of predicted 0.66 (0.35 to 1.22) 0.18 NIc
 ≥ 80% of predicted Reference
DLCO
 < 80% of predicted 0.74 (0.34 to 1.60) 0.44 NIc
 ≥ 80% of predicted Reference
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however, associations differed between males and females 
and between younger and older patients.
A BMI < 18.5 kg/m2 and poor WHO performance sta-
tus were independently associated with poor tolerance of 
cCHRT. Studies investigating the relationship between 
WHO performance status and tolerance of cCHRT in lung 
cancer are lacking. Furthermore, one study indicated that 
malnutrition, especially in overweight patients, negatively 
influences survival of stage III NSCLC [35]. Although sig-
nificance disappeared in multivariable analyses, low hand-
grip strength also seemed to be associated with poorer toler-
ance of cCHRT. This is in line with previous studies which 
have shown an association between low handgrip strength 
before treatment and an increased risk of poor treatment 
tolerance in patients with oesophageal and colorectal cancer 
[36–38]. Results of the current study and previous studies 
therefore suggest that BMI < 18.5 kg/m2, poor WHO per-
formance status and low handgrip strength before treatment 
might have an added value in identifying patients at high risk 
of poor tolerance of cCHRT.
Additionally, poor tolerance of cCHRT was most signifi-
cantly associated with poorer survival, even after adjustment 
for patient characteristics. These findings suggest that it is 
important to identify which patients are expected to benefit 
from this radical treatment with cCHRT for discussing the 
balance between quality of life and survival with patients. 
Low FFMI, poor WHO performance status and low handgrip 
strength were significantly associated with worse survival; 
however, associations differed between males and females 
and between younger and older patients. A previous study 
showed an association between low FFMI, poor WHO per-
formance status and low handgrip strength and worse sur-
vival in patients with NSCLC [39, 40]. In previous research 
[41], the prognostic value of low DLCO to predict worse 
survival in Japanese patients with stage III NSCLC has also 
been indicated. Although these results were also shown in 
univariate analyses in the current study, unfortunately DLCO 
could not be included in multivariable analyses due to miss-
ing values. Future studies should focus on this promising 
parameter.
Poor WHO performance status, low FFMI and not tol-
erating cCHRT were significantly associated with poorer 
survival in male patients, whereas this was only poor 
WHO performance status in female patients. These differ-
ences might be explained by the small number of female 
patients in this study, resulting in a lack of statistical power. 
In patients < 70 years, poor WHO performance status, low 
handgrip strength and not tolerating cCHRT were signifi-
cantly associated with poorer survival. In older patients, age 
(as a continuous variable) and low FFMI were significantly 
associated with poorer survival. It is plausible that relatively 
fit older patients aged ≥ 70 years were selected for cCHRT in 
this observational study in everyday clinical practice, which 
means that numbers of vulnerable older patients might have 
been too small for reaching significance [5].
Physical status parameters are often associated with treat-
ment intolerance and worse survival in patients with cancer, 
especially in those undergoing surgery [43, 44]. Despite this, 
Fig. 1  Kaplan–Meier survival curves. a Kaplan–Meier survival 
curve according to sex in non-small cell lung cancer patients receiv-
ing concurrent chemoradiation (Log rank: P = 0.04). b Kaplan–Meier 
survival curve according to age groups in non-small cell lung cancer 
patients receiving concurrent chemoradiation (Log rank: P = 0.05). 
c Kaplan–Meier survival curve according to tolerance of cCHRT in 
non-small cell lung cancer patients receiving concurrent chemoradia-
tion (Log rank: P = 0.01)
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1 3
the association between a combination of these pretreatment 
physical status parameters and tolerance of cCHRT and sur-
vival among patients with stage III NSCLC has not been 
investigated before. The large sample size in this population 
truly reflected clinical practice and quality and completeness 
of included data was high, except for DLCO. Using real-world 
data means that patients who were sufficiently fit for cCHRT 
were included as advised by European guidelines. [45, 46]. 
Because of this possible selection bias, results for the associa-
tions between pretreatment physical performance parameters 
and tolerance of CHRT might differ for vulnerable patients. 
This study demonstrates that pretreatment physical status 
Table 3  Univariate and multivariate hazard ratios and 95% CI for associations between physical status parameters and survival in patients with 
stage III NSCLC
BMI body mass index, cCHRT concurrent chemoradiation, CI confidence interval, DLCO diffusing capacity for carbon monoxide; FEV1 forced 
expiratory volume in 1 s, FFMI fat-free mass index, HR hazard ratio, NI not included, NS not significant, NSCLC non-small cell lung cancer, 
WHO World Health Organization
a Not included when P-value ≥ 0.10
b Males FFMI < 17 kg/m2 and females FFMI < 15 kg/m2
c < 10th percentile of established normative values [33]
d No = received radiation dose was less than the prescribed radiation dose
e Yes = received radiation dose was at least equal to the prescribed radiation dose




Univariate Multivariate without tolerance of 
cCHRT
Multivariate with tolerance of 
cCHRT
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age
 < 70 years 24 Reference 0.05 Reference 0.05 Reference 0.08
 ≥ 70 years 19 1.23 (0.98 to 1.51) 1.24 (1.00 to 1.54) 1.22 (0.98 to 1.51)
Sex
 Male 21 1.24 (1.01 to 1.52) 0.04 NS NS
 Female 26 Reference
WHO performance status
 0–1 24 Reference  ≤ 0.01 Reference  ≤ 0.01 Reference  ≤ 0.01
 ≥ 2 10 1.91 (1.33 to 2.74) 1.77 (1.23 to 2.57) 1.73 (1.19 to 2.51)
Charlson comorbidity index
 0–3 21 Reference 0.31 NIa NIa
 ≥ 4 23 1.11 (0.91 to 1.35)
BMI
 Underweight 15 1.28 (0.85 to 1.92) 0.23 NIa NIa
 Normal/overweight 23 Reference
FFMI
 Normal FFMI 24 Reference 0.04 Reference 0.07 Reference 0.08
 Low  FFMIb 21 1.27 (1.02 to 1.56) 1.24 (0.98 to 1.57) 1.23 (0.97 to 1.56)
Handgrip strength
 Normal 23 Reference 0.03 NS NS
  Lowc 17 1.32 (1.02 to 1.70)
FEV1
 < 80% of predicted 21 1.13 (0.91 to 1.40) 0.28 NIa NIa
 ≥ 80% 23 Reference
DLCOf
 < 80% 21 1.42 (1.09 to 1.85) 0.01e NIa NIa
 ≥ 80% 29 Reference
Tolerance of cCHRT
  Nod 11 1.56 (1.12 to 2.18) 0.01 NIa 1.55 (1.11 to 2.17) 0.01
  Yese 23 Reference Reference
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parameters are associated with both tolerance of cCHRT and 
survival. However, in elderly patients, the impact of toxicities 
on quality of life (especially preserving independency) may 
be just as important as the prolongation of life expectancy. 
Future evidence on the associations between pretreatment 
physical status parameters and quality of life and functional 
recovery is essential to make adequate treatment decisions 
with patients. In addition, physical tests might also be used 
Table 4  Multivariate hazard ratios without and with treatment tolerance for associations of pretreatment patient characteristics and physical sta-
tus parameters with tolerance of cCHRT and survival in patients with stage III NSCLC stratified for sex and age
cCHRT concurrent chemoradiation, CI confidence interval, FFMI fat-free mass index, HR hazard ratio, NI not included, NS not significant, 
NSCLC non-small cell lung cancer, WHO World Health Organization
a Males FFMI < 17 kg/m2 and females FFMI < 15 kg/m2
b < 10th percentile of established normative values [33],
c No = received radiation dose was less than the prescribed radiation dose,
d Yes = received radiation dose was at least equal to the prescribed radiation dose,
e Not included as P value ≥ 0.10
Multivariate without treatment tolerance Multivariate with treatment tolerance
Male Female Male Female
HR (95% CI) P value HR ( 95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age
 < 70 years Reference 0.08 NS NS NS
 ≥ 70 years 1.26 (0.97 to 1.63)
WHO performance status
 0–1 NS Reference ≤ 0.01 Reference 0.07 0.07 ≤ 0.01
 ≥ 2 2.56 (1.38 to 4.76) 1.54 (0.97 to 2.42) 2.56 (1.38 to 4.76)
FFMI
 Normal FFMI Reference ≤ 0.01 NS Reference ≤ 0.01 NS
 Low  FFMIa 1.65 (1.24–2.21) 1.60 (1.19 to 2.14)
Handgrip strength
 Normal NS NS NS NS
  Lowb
Tolerance of cCHRT
  Noc NIe NIe 1.85 (1.24 to 2.77) ≤ 0.01 NS
  Yesd Reference
Age < 70 years Age < 70 years Age < 70 years Age < 70 years
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age, continuous per year NS 1.07 (1.01 to 1.13) 0.02 NS 1.07 (1.01 to 1.13) 0.02
Sex
 Male NS NS NS NS
 Female
WHO performance status
 0–1 Reference 0.02 NS Reference 0.02 NS
 ≥ 2 1.76 (1.09 to 2.84) 1.81 (1.12 to 2.92)
FFMI
 Normal FFMI NS Reference 0.02 NS Reference 0.02
 Low  FFMIa 1.60 (1.08 to 2.39) 1.60 (1.08 to 2.39)
Handgrip strength
 Normal Reference 0.01 NS Reference 0.02 NS
  Lowb 1.52 (1.09 to 2.12) 1.47 (1.06 to 2.06)
Tolerance of cCHRT
  Noc NIe NS 1.89 (1.26 to 2.82)  ≤ 0.01 NS
  Yesd Reference
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to identify high-risk patients who might benefit from lifestyle 
interventions before and during cancer treatment [47]. Another 
limitation of this study is the lack of patient-related parameters 
such as nutritional status, psychological distress and social 
support. These important functional status parameters are 
recommended by the American Society of Clinical Oncology 
(ASCO) guidelines for older and/or more vulnerable patients 
receiving chemotherapy [42]. It is important to know the rate 
of adverse events in order to determine the definition of poor 
treatment tolerance. Ideally, this is derived from both the dose 
intensity of radiotherapy and the dose intensity for chemother-
apy. Unfortunately, the latter was not available in the database 
from the clinic for radiotherapy. It is recommended to include 
this information in a subsequent study. Furthermore, it would 
be useful to determine whether these physical status param-
eters are also associated with treatment tolerance in stage III 
NSCLC patients undergoing less aggressive treatment, such 
as immunotherapy.
In conclusion, in patients with stage III NSCLC receiving 
cCHRT, poor WHO performance status and BMI < 18.5 kg/
m2 were independently associated with tolerance of cCHRT, 
and both physical status parameters and intolerance of cCHRT 
were independently associated with poorer survival. Treat-
ment selection for patients with stage III NSCLC is already 
well underway. Further improvements may be established by 
paying attention to the risk of intolerance of cCHRT, which 
increases the patient’s risk of death and decreases quality of 
life. Optimizing physical status in patients at risk for intoler-
ance of cCHRT can be a next step for improving treatment 
outcomes.
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